Research | Pipeline
Biogen MA Inc. 225 Binney Street Cambridge, MA 02142 United States PROTOCOL NUMBER: 251PP301 / NCT03068468 Biogen Idec Research
Medscape - After disappointing trial results, Biogen will discontinue development of gosuranemab for PSP and other primary tauopathies. http://ms.spr.ly/6185Tn3JH | Facebook
Biogen on Twitter: "#DYK…Progressive supranuclear palsy (#PSP) is a neurodegenerative disorder that affects the brain cells controlling balance, walking, coordination, eye movement, speech, swallowing and thinking. #AANAM https://t.co/uYb551MjJi" / Twitter
PSP — Coleen Heaver
Phil's Journal: My Good Friend Is the First to Receive Biogen's Alzheimer's Drug in New Trial - Being Patient
Biogen MA Inc. 225 Binney Street Cambridge, MA 02142 United States PROTOCOL NUMBER: 251PP301 / NCT03068468 Biogen Idec Research
Biogen Headquarters And Global Offices
Biogen Discontinues Gosuranemab Trial in Progressive Supranuclear Palsy
Anti-Tau Drugs for PSP Move into Phase II - CurePSP
Overview of Tau immunotherapies in clinical trial. Indicated are... | Download Scientific Diagram
Biogen on Twitter: "Our #MultipleSclerosis (#MS) and progressive supranuclear palsy (#PSP) research will be highlighted in the poster sessions today at #AANAM https://t.co/4HA0yQOW8X" / Twitter
Biogen chalks up another failure, but investors' eyes remain firmly on Alzheimer's | Fierce Biotech
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial | Nature Medicine
Biogen deals the tau pipeline another blow | Evaluate
Bristol-Myers offloads anti-tau, DMD assets to Biogen, Roche for $470M upfront, $615M in milestones | Fierce Biotech
Biogen Licenses Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb - Pharmaceutical Processing World
Biogen's Tau Antibody for Progressive Supranuclear Palsy Fails Trial | BioSpace
AbbVie Discontinued a Drug Trial. Biogen Stock Is Falling. | Barron's
Cover Layout Presentation name
Biogen pays $300M to Bristol-Myers for another potential Alzheimer's drug - Boston Business Journal
Biogen - Pioneers In Neuroscience
Biogen on Twitter: "Chris Henderson, VP, Neuromuscular and Movement Disorders Research Unit, highlights the importance of an early Progressive Supranuclear Palsy (PSP) diagnosis #PSPAwareness https://t.co/xDnZaZYYhT" / Twitter
Biogen Ends Trial of Its Drug for PSP - CurePSP
